May 31, 2022

Press release

FluoGuide A/S publishes interim report for the period January – March 2022

Copenhagen, Denmark, 31 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

May 23, 2022

Press release

FluoGuide publish the presentation of FG001 results from the first clinical trial in aggressive brain cancer

Copenhagen, Denmark, 23 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the presentation of the... [Read more]

May 19, 2022

Press release

Minutes from Annual General Meeting in FluoGuide A/S

Copenhagen, Denmark, 19 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) held its annual general meeting on 18 May 2022.... [Read more]

May 6, 2022

Press release

FluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 2022

Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the... [Read more]

May 5, 2022

News

ØU Life Science initiate research coverage on FluoGuide

Copenhagen, Denmark, 5 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to share ØU Life Sciences research report... [Read more]

May 2, 2022

Press release

Annual General Meeting Copenhagen, Denmark, 2 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby convenes an annual general meeting to be held on 18 May 2022.

To the shareholders of FluoGuide A/S The board of directors hereby convenes an annual general meeting of FluoGuide to be held... [Read more]

April 20, 2022

News

FluoGuide is presenting at Redeye’s Orphan Drugs on the 27 April 2022

Copenhagen, Denmark, 20 April 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that Morten Albrechtsen, CEO of... [Read more]

April 1, 2022

Press release

FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer

Copenhagen, Denmark, 01.04.2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been shown safe and... [Read more]

March 30, 2022

Press release

FluoGuide A/S publishes Year-end and annual report for the fiscal year 2021

Copenhagen, Denmark, 30 March 2022  – FluoGuide A/S (“FluoGuide” or the “Company”) hereby publishes its annual report for the fiscal year... [Read more]